omniture
I-Mab-天境生物科技(上海)有限公司

Latest News

I-Mab Announces Preclinical Data on Differentiated Anti-C5aR Antibody TJ210/MOR210 at SITC 2020

SHANGHAI and GAITHERSBURG, Md., Nov. 11, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2020-11-11 21:00 4318

I-Mab Reports Phase 1 Clinical Trial Data of Highly Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab at the 2020 SITC Annual Meeting

SHANGHAI and GAITHERSBURG, Md., Nov. 9, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), ...

2020-11-09 21:12 2851

I-Mab Announces Upcoming Participation at November Conferences

SHANGHAI, China, and GAITHERSBURG, MD., Oct. 28, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq...

2020-10-28 20:00 2036

I-Mab to Present Preclinical Data of TJ210 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

SHANGHAI and GAITHERSBURG, Md., Oct. 27, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2020-10-27 20:05 3651

I-Mab Receives China CDE Approval to Initiate Phase 3 Clinical Trial of Eftansomatropin in Pediatric Patients with Growth Hormone Deficiency

SHANGHAI and GAITHERSBURG, Md., Sept. 30, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB)...

2020-09-30 20:00 10903

I-Mab Announces China NMPA Clearance for Phase 1 Clinical Trial of Lemzoparlimab in Relapsed or Refractory Advanced Lymphoma

SHANGHAI and GAITHERSBURG, Md., Sept. 21, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB)...

2020-09-21 20:00 5261

MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer

PLANEGG/MUNICH, Germany and SHANGHAI, China, Sept. 17, 2020 /PRNewswire/ -- MorphoSys AG (FSE: MOR;...

2020-09-18 04:05 9945

I-Mab Announces Upcoming Participation at September Conferences

SHANGHAI and GAITHERSBURG, Md., Sept. 8, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2020-09-08 20:00 8636

I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium

SHANGHAI and GAITHERSBURG, Md., Sept. 4, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2020-09-04 19:01 10145

AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy

NORTH CHICAGO, Illinois and SHANGHAI, China, Sept. 4, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) and ...

2020-09-04 19:00 9589

I-Mab Reports Financial Results for the Six Months Ended June 30 and Provides Corporate Update

Positive preliminary clinical trial results for lemzoparlimab (TJC4) demonstrate a differentiated d...

2020-08-31 19:00 12995

I-Mab Announces First Patient Dosed in Phase 1b Study of Plonmarlimab in Rheumatoid Arthritis in China

SHANGHAI and GAITHERSBERG, Md., Aug. 17, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2020-08-17 20:00 2705

I-Mab to Report Financial Results for the Six Months Ended June 30, 2020 and Provide Corporate Update on August 31, 2020

SHANGHAI and GAITHERSBURG, Md., Aug. 6, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), ...

2020-08-06 20:30 13814

China NMPA Accepts IND Application for Eftansomatropin Pivotal Trial in Pediatric Patients with Growth Hormone Deficiency

SHANGHAI and GAITHERSBERG, Md., Aug. 4, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), ...

2020-08-04 20:17 14689

I-Mab Drives Commercialization Strategy with Appointment of Ivan Yifei Zhu as Chief Commercial Officer

SHANGHAI and GAITHERSBERG, Md., July 28, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2020-07-28 20:22 9457

I-Mab Announces Authorization of Stock Repurchase Program up to $20 Million

SHANGHAI and GAITHERSBURG, Md., July 15, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2020-07-16 04:15 21457

I-Mab and ABL Bio to Present Preclinical Data for Joint Bispecific Antibody Program at the 2020 American Association for Cancer Research Virtual Meeting II

SHANGHAI and GAITHERSBURG, Md., June 12, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2020-06-12 20:00 6250

I-Mab Announces Upcoming Participation at June Conferences

SHANGHAI and GAITHERSBURG, Md., May 29, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), ...

2020-05-29 20:00 5149

I-Mab Reports Interim Results from Part 1 Study for Anti-GM-CSF Antibody TJM2 to Treat COVID-19 Patients with Cytokine Release Syndrome

SHANGHAI and GAITHERSBURG, MD, May 27, 2020 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a clinical-stage...

2020-05-28 04:05 952

I-Mab and Genexine Announce China NMPA Clearance for Phase 2 Clinical Trial of TJ107/HyLeukin-7™ in Glioblastoma Multiforme

SHANGHAI, GAITHERSBURG, Md. and SEOUL, South Korea, May 21, 2020 /PRNewswire/ -- I-Mab (NASDAQ: IMA...

2020-05-21 20:00 5142
123